CYTOKINETICS INC

CYTK 10-K · FY 2025
API behind this page

CYTK FY 2025 request

Playground key active
Request URL /api/financials?ticker=CYTK&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 88,039 18,474 +376.6%
Show Product Lines breakouts
Collaboration Revenues [Member] 8,686 3,474 +150.0%
Collaboration Revenues [Member] · Bayer License Agreement [Member] 8.1 0.1 +8000.0%
Collaboration Revenues [Member] · CN 0.6 3.3 -81.8%
License and Milestone Revenues [Member] 79,353 15,000 +429.0%
License and Milestone Revenues [Member] · Accounting for the License and Collaboration Agreements in China [Member] 15 — —
License and Milestone Revenues [Member] · Bayer License Agreement [Member] 64.3 — —
Research & Development 416,026 339,408 +22.6%
General & Administrative 284,271 215,314 +32.0%
Operating Expenses 700,297 554,722 +26.2%
Operating Income -612,258 -536,248 -14.2%
Interest Expense -45,579 -37,701 -20.9%
Non Cash Interest Expenses On Liabilities Related To Revenue Participation Right Purchase Agreements -58,289 -48,811 -19.4%
Non-Operating Income (Expense) 48,420 51,534 -6.0%
Derivative Gain Loss On Derivative Net 4,200 1,300 +223.1%
Show Debt Instrument breakouts
RP Multi Tranche Loan [Member] -4,200 -1,300 -223.1%
Liabilities Fair Value Adjustment -200 -19,600 +99.0%
Debt Conversion Expense -121,249 — —
Net Income -784,955 -589,526 -33.2%
Show Equity Components breakouts
Retained Earnings -784,955 -589,526 -33.2%
EPS (Basic) -6.54 -5.26 -24.3%
EPS (Diluted) -6.54 -5.26 -24.3%
Wtd Avg Shares (Basic) 120,103 111,979 +7.3%
Wtd Avg Shares (Diluted) 120,103 111,979 +7.3%
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax -990 2,153 -146.0%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -990 2,153 -146.0%
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax -778 255 -405.1%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -778 255 -405.1%
Comprehensive Income -786,723 -587,118 -34.0%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 122,518 94,857 +29.2%
Available For Sale Securities Debt Securities Current 759,703 981,157 -22.6%
Accounts Receivable 17,764 16,650 +6.7%
Show Type Of Arrangement breakouts
Bayer License Agreement [Member] 2.6 — —
Sanofi License Agreement 15.1 — —
Prepaid Expenses & Other Current Assets 16,990 15,276 +11.2%
Total Current Assets 916,975 1,107,940 -17.2%
Non-Current Assets
Available For Sale Securities Debt Securities Noncurrent 335,048 145,055 +131.0%
Property, Plant & Equipment 79,194 65,815 +20.3%
Operating Lease Right-of-Use Assets 75,979 75,158 +1.1%
Show Geography breakouts
CH · Zug Lease [Member] 2.6 — —
PA · Amended Radnor Lease for Existing and Additional Space [Member] 2.4 — —
Other Non-Current Assets 17,341 7,705 +125.1%
Total Assets 1,424,537 1,401,673 +1.6%
Current Liabilities
Accounts Payable 22,337 20,369 +9.7%
Accrued Liabilities 83,278 55,323 +50.5%
Operating Lease Liability Current 19,111 18,978 +0.7%
Current Portion of Long-Term Debt 41,181 11,520 +257.5%
Derivative Liabilities Current 31,100 11,300 +175.2%
Deferred Revenue 1,612 52,370 -96.9%
Other Liabilities Current 3,833 9,814 -60.9%
Total Current Liabilities 202,452 179,674 +12.7%
Non-Current Liabilities
Long-Term Debt 246,384 93,227 +164.3%
Convertible Notes Noncurrent 869,597 552,370 +57.4%
Operating Lease Liabilities 107,970 112,582 -4.1%
Total Liabilities 2,084,162 1,537,045 +35.6%
Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
RP Multi Tranche Loan [Member] · Term Loan Tranche 1, Tranche 4, Tranche 5, and Tranche 6 [Member] 266,544 — —
Other Liabilities
Liabilities Related To Revenue Participation Right Purchase Agreement Net 520,559 462,192 +12.6%
Liabilities Related To R P I Transactions Fairvalue 137,200 137,000 +0.1%
Stockholders' Equity
Common Stock 123 118 +4.2%
Additional Paid In Capital Common Stock 2,826,341 2,563,876 +10.2%
Accumulated Other Comprehensive Income 630 2,398 -73.7%
Retained Earnings -3,486,719 -2,701,764 -29.1%
Total Stockholders' Equity -659,625 -135,372 -387.3%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 630 2,398 -73.7%
Additional Paid In Capital 2,826,341 2,563,876 +10.2%
Common Stock 123 118 +4.2%
Retained Earnings -3,486,719 -2,701,764 -29.1%
Total Liabilities & Equity 1,424,537 1,401,673 +1.6%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Net Income -784,955 -589,526 -33.2%
Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement 58,367 48,917 +19.3%
Stock-Based Compensation 112,286 97,840 +14.8%
Non Cash Lease Expense 5,648 4,314 +30.9%
Depreciation & Amortization 10,125 9,531 +6.2%
Realized Investment Gains Losses -25 -19 -31.6%
Interest Receivable And Amortization On Investments -15,977 -32,515 +50.9%
Paid In Kind Interest 22,901 11,559 +98.1%
Change in Accounts Receivable -1,114 -15,367 +92.8%
Change in Prepaid & Other Assets -2,933 -2,438 -20.3%
Increase Decrease In Accounts Payable Trade 2,663 -4,483 +159.4%
Increase Decrease In Deferred Revenue -50,758 52,370 -196.9%
Increase Decrease In Accrued Liabilities 33,603 14,182 +136.9%
Increase Decrease In Operating Lease Liabilities -10,839 -7,244 -49.6%
Change in Other Liabilities -6,250 -1,356 -360.9%
Net Cash from Operations -510,009 -395,890 -28.8%
Investing Activities
Purchases of Investments -1,063,173 -1,293,416 +17.8%
Investment In Non- Marketable Equity Security -5,000 — —
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 1,103,645 744,225 +48.3%
Proceeds From Sale Of Available For Sale Securities Debt 6,001 — —
Capital Expenditures -24,807 -3,906 -535.1%
Net Cash from Investing 16,666 -553,097 +103.0%
Financing Activities
Finance Lease Principal Payments -204 -939 +78.3%
Repayments Of Long Term Debt -10,809 -8,679 -24.5%
Repayment Of Convertible Debts -402,500 — —
Proceeds From Convertible Debt 729,460 — —
Proceeds From Draw On R P I Multi Tranche Loan 175,000 200,000 -12.5%
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 35,979 53,016 -32.1%
Tax Withholding for Share Compensation -2,468 -19,631 +87.4%
Net Cash from Financing 524,458 930,611 -43.6%
Amortization of Financing Costs (FY) — — —
Show Debt Instrument breakouts
2026 Notes [Member] 119 115 +3.5%
2027 Notes [Member] 2,600 3,265 -20.4%
2031 Notes [Member] 964 — —
Show Research And Development Arrangement Contract To Perform For Others By Type breakouts
Royalty Agreement Terms 78 106 -26.4%
Supplemental
Interest Paid 22,914 25,970 -11.8%
Right Of Use Asset Obtained In Exchange For Operating Lease Liability 6,255 481 +1200.4%
Show Geography breakouts
PA · Amended Radnor Lease for Existing and Additional Space [Member] 1.1 — —
Unpaid Capital Expenditures 2,650 3,345 -20.8%
Fair Value Of Stock Issued For Convertible Note 107,920 — —
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -715 209 -442.1%
Net Change in Cash 30,400 -18,167 +267.3%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 125,632 95,232 +31.9%

Values in thousands USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key